Biocon Ltd has issued ₹1,800 crore worth of Commercial Papers (CPs) on a private placement basis, carrying an interest rate of 6.85% and an 88-day tenure. The instruments, rated IND A1+, are proposed to be listed on the NSE, with maturity set for March 20, 2026.
Biopharmaceutical major Biocon Limited today announced the issuance of Commercial Papers (CPs) worth ₹1,800 crore through private placement to meet short-term funding requirements. The short-term debt instruments, carrying a coupon rate of 6.85%, were allotted on December 22, 2025, and will mature on March 20, 2026.
The CPs, rated IND A1+ by India Ratings, reflect Biocon’s strong credit profile and liquidity position. The issue has been subscribed by leading investors, including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life Mutual Fund, highlighting institutional confidence in the company’s near-term financial stability.
These instruments carry no charge or security over assets and will be listed on the National Stock Exchange (NSE), ensuring wider transparency for investors.
Key Highlights
-
Issue Size: ₹1,800 crore through private placement.
-
Tenure: 88 days, maturing on 20 March 2026.
-
Interest Rate: Fixed coupon of 6.85%.
-
Allottees: SBI MF, Axis MF, Aditya Birla Sun Life MF.
-
Credit Rating: IND A1+ (high safety).
-
Listing: Proposed on NSE.
-
Security: Unsecured; no asset charge created.
Source: NSE Corporate Filings, BSE Announcements